Trial Profile
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Jan 2023 Results of a multicenter phase 2 study (DASA-PegIFN study published in the British Journal of Haematology
- 07 Feb 2020 Status changed from active, no longer recruiting to completed.
- 11 Dec 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Oct 2018 as reported by ClinicalTrials.gov.